Mar

7

BioCurex Inc. (Symbol: BOCX)

Filed Under Biotechnology & Drugs | Leave a Comment

There are over 8 million cancer patients in North America, with approximately 1 million more people developing cancer each year. Over one third of the population will develop cancer at some point during their life and over one-half a million people die from cancer each year. The new incidences of cancer, along with the maintenance of persons living with cancer continue to increase the demand for cancer products on a large scale.

The present world market for cancer therapeutics alone is approximately US$ 6.5 billion with an expected increase towards US$15 billion by the year 2002. The National Cancer Institute estimates the overall annual costs for cancer in the U.S. at US$104 billion with US$35 billion in direct medical costs and the remainder in productivity and mortality-related costs. Approximately one half of the direct costs are related to the treatment of breast, lung and prostate cancers. On a global basis, costs associated with cancer related illnesses are estimated at more than $150 billion. This is where BioCurex Inc. (Symbol: BOCX) enters the market.

BioCurex Inc. is currently developing these following products:

HISTOLOGY AND CYTOLOGY BioCurex’s Histo-RECAF™ is a special cancer detection kit for tissues that stains cancer cells brown, clearly distinguishing them from normal healthy cells. Pathologists are able to easily identify cancer cells under a conventional microscope for making a diagnosis.

LEUKEMIA Using our technology, leukemia cells can be “lit up” so that only infected blood cancer cells are isolated for targeted treatment. The clear implication of the BioCurex technology is that physicians can detect any recurrence of the blood cancer at a very early stage using equipment that is available today.

BLOOD AND SERUM TESTS Using our technology, a basic blood test can determine if a patient has cancer. Cancer cells shed our cancer marker RECAF™ into the blood stream where it is detected. Because of its powerful detection capability and simple execution, the Serum-RECAF™ will be a standardized blood test widely available in any clinical laboratory. Physicians can then use Serum-RECAF™ as frequently as required for both the initial screening of patients with symptoms, and monitoring of those patients who have been previously treated for cancer.

TUMOR IMAGING Once cancer has been diagnosed, it is crucial to determine its location and size. Because the RECAF™ technology effectively detects cancer cells, cancer tissue can be targeted with special compounds administered to the patient. Since only cancer cells are selected, tumor locations can then be imaged using standard equipment.Recently they announced that Dr. Steward Sell has joined the Scientific Advisory Board of BioCurex Inc. Dr. Steward Sell is an internationally renowned physician and scientist in the cancer and stem cell fields. In addition to obtaining his medical degree at the University of Pittsburgh, his residency in Pathology at Massachusetts General Hospital, and research in Immunology at National Institute of Health, Bethesda and University of Birmingham, he has also received many awards including the Virchow Award (in honor of the recognized father of pathology), Legacy Laureate of the University of Pittsburgh, (which recognizes the University’s most distinguished graduates), Distinguished Scientist by the International Academy of Tumor Marker Oncology, the Gary Miller Memorial Award from the American Association for Cancer Research (AACR) and recently, a special award from the AACR for his contributions to teaching principles of cancer biology over the last 25 years. Yupp, that’s a pretty distinguished resume, if I might add :)

Below is their stock performance for the past 6 months.

Source: http://biocurex.com

Quote of the Day:
The stocks I try to buy are the very stocks that traditional fund managers try to overlook. In other words, I continue to think like an amateur as frequently as possible. - Peter Lynch

Feb

5

Amarin Corp plc (Symbol: AMRN)

Filed Under Biotechnology & Drugs | Leave a Comment

Amarin Corp plc is a neuroscience company focused on the research, development and commercialisation of novel drugs for the treatment of central nervous system disorders.

I’m still kicking myself for not buying this stock when I had a chance to. A month ago, I added this stock to my “Investment to Watch” List. At that time, the stock was traded at $1.95/share.

And now? It’s $3.32/share!!!

I gotta tell you, it’s really hard to find a cheap biotech stock. But I was pretty lucky finding this one. Had I bought 1,000 shares of it a month ago, I would’ve made $1,370 by now.

In the past few months, a lot of things have happened in the company. They announced $2 million equity investment by Dr. Tony Ryan (who is a Director of Ryanair Holdings and was a founder and former Chairman of GPA Group plc, an operating lessor of commercial aircraft. Dr. Ryan also served as Executive Chairman of GE Capital Aviation Services, Limited), preliminary results from Parkinson’s disease pre-clinical program using Miraxion (studies show that Miraxion has neuroprotective effects in Parkinson’s disease), they licensed Phase IIb/III Drug for the treatment of fatigue in multiple sclerosis to Multicell Inc., and they raised another $24 million in private placement.

Here’s how their price/share has been performing in the past 30 days:

What do you think, huh? This one is definitely a good investment.

As I said before, I’m still kicking myself for not getting this one a month earlier. On the other hand, it’s still not too late to invest your money in this company…

Quote of the Day:
Great investment opportunities come around when excellent companies are surrounded by unusual circumstances that cause the stock to be misappraised. - Warren Buffett

Nov

29

Anti-Cancer Drug??

Filed Under Biotechnology & Drugs | Leave a Comment

Ever heard of Callisto Pharmaceuticals, Inc. (Symbol: KAL)…..??

They are one of the companies who are currently in developing new drug treatments in the fight against cancer and other serious health threats. They recently announced that their anti-cancer drug candidate Atiprimod has been further recognized by the scientific community - which is going to lead them to a second oral presentation of research data at the annual meeting of American Society of Hematology (ASH) in Atlanta, GA.

They are also going to present findings of an animal-based study to investigate the effet of Atiprimod on multiple myeloma tumors (which is also known as incurable form of blood cancer). The animal study observed that Atiprimod produced experimentally significant reduction in tumor levels.

The stock is currently traded at $1.1/share. I’m not really sure when the price is going to hit through the roof; however, one thing for sure is this stock is definitely a great long-term investment.

Quote of the Day:
In the search for companies to acquire, we adopt the same attitude one might find appropriate in looking for a spouse: it pays to be active, interested, and open-minded, but it does not pay to be in a hurry. - Warren Buffett

Jan

11

Motion DNA (Symbol: MTDX)

Filed Under Biotechnology & Drugs | Leave a Comment

Stumbled upon this one when I did my research last night. This company, Motion DNA (Symbol: MTDX) was founded to commercialize its innovative, diagnostic motion capture system that monitors and identifies physical characteristics for improvement of the motions of the human body. The company markets this technology to medical professionals, sports organizations, professional athletes, and even large companies looking to prevent physical strain and injury to its employees. They provide analyses and detailed reports to its licensees and consumers with solutions for preventing injuries, identifying physical limitations, diagnosing pre-existing injuries related to biomechanics, and improving physical performance levels.

Looking at their historical data, I’m little bit sceptical if this stock is going to perform well in the future. A month ago, they were traded at 0.18/share; 3 months ago they were traded as high as $0.30/share. Hell a year ago, they were traded at $1/share. Currently they’re traded at $0.01/share. There must be a good reason why the price dropped a lot within one year.

Recently there was an article about them published in Business Wire. Here it is:

“Motion DNA Corporation (OTC:MTDX) officials announced today an upcoming marketing schedule of events for 2004 and 2005. The marketing schedule kicks off with demonstrating its products and services at the upcoming Baseball Tradeshow in Anaheim, California, December 10-12, 2004. Company officials expect to expose the company’s technology to professional baseball teams of all levels at the convention. Coaches, front office executives, and medical professionals representing teams from the MLB and minor league organizations are expected to attend the tradeshow, which is held in conjunction with the Baseball Winter Meetings for professional teams. Representatives in baseball from collegiate and professional teams have expressed an increasing interest in Motion DNA’s analysis primarily for evaluating the risks of shoulder and elbow injuries in pitchers. An injury to a key player can cost a professional team millions of dollars each year. The losses add up when teams look at wages paid to the injured player, lost gate receipts, and missed post season revenues due to the injury to one player.
“Our goal is annual testing for athletes involved in sports where there is a high risk of injury to a particular group. The fee for Motion DNA’s full analysis for a pitcher ranges from $200 to $900 per player depending upon our report’s detail and could add up to over $200,000 per team,” said Zig Ziegler, President of Motion DNA.
“However, the company offers a much lower flat fee for annual contracts with a schedule consisting of 4 tests annually for pitchers only conducted at a site determined by the client.”
Company officials believe that if major league baseball requires its at-risk athletes to be tested, collegiate and high school programs are sure to follow suit, along with other sports.
“If I am the owner of a professional team spending millions of dollars on even one player … counting on them to stay healthy, this is just a small fee to help ease my mind and insure my product (which in today’s sports business world is the athlete) works properly,” added Ziegler. (http://biz.yahoo.com/bw/041128/285028_1.html November 28, 9:40 am - Yahoo Finance)

So what do you think, huh? At $0.01/share, this stock might not be a bad investment. It’s cheap, judging from the services offered - looks like they still have a good potential to become a bigger company, and it’s a low risk. Put in a hundred bucks, you’ll get 1,000 shares. When the price hits 50 cents or something, you’ll cash out $500…Not bad, huh?

Quote of the Day:
Wealth consists not in having great possessions, but in having few wants. - Epicurus

Oct

22

Diabetes

Filed Under Biotechnology & Drugs | Leave a Comment

Diabetes is the world’s fastest-growing disease. It is responsible for a QUARTER of all deaths in many parts of the world. (Many more people die from diabetes than AIDS.)

But every so often, something wonderful comes along that changes the lives of millions of people. It is called: Pulse Insulin Therapy, and hundreds of thousands of people will be given new lives.

Never before has a single small public company played so dominant a role in the birth of such a large “industry.” This small public company, Diabetic Treatment Centers of America (Symbol: DBTC) offers this new product called Pulse Insulin Theraphy (PIT). PIT treatment will permit hundreds of thousands of patients to live again. As only diabetics can truly know what that means. Thus, Diabetic Treatment Centers of America is presenting itself as a rare opportunity for early investors.

Who is Diabetic Treatment Centers of America?
Diabetic Treatment Centers of America offers a true breakthrough in diabetes treatment: Pulse Insulin Therapy (PIT). Recently approved for reimbursement by Medicare and major insurance companies, PIT is the only treatment available that can effectively slow, stop and reverse the chronic complications associated with diabetes. Diabetic Treatment Centers of America is the only public company pioneering this advance, in the world’s fastest-growing industry.

What Pulse Insulin Therapy DOES…
PIT is the first effective treatment that actually stops and even reverses the terrible complications, returning a diabetic to a more normal life. A diabetic visits a clinic for three one-hour treatments over a six hour period, sits in a chair attached to an IV, along with the Bionica pump and a RQ apparatus. The Bionica pump mimics that particular patient’s liver needs, to reestablish the ability to metabolize carbohydrates. Meanwhile the RQ equipment measures the precise carbohydrate and lipid metabolic levels. This monitors how well the body is regaining normality. The patient returns once a week. Within a few weeks, the patient should start noticing a difference. Within a few months his metabolism should be restored to near normal, and the diabetic deterioration will slow, stop and even reverse itself.

Now diabetics can lead normal lives with the greatest FDA-approved breakthrough in over 80 years! Complications from this terrible disease can now be stopped — even reversed! This diabetes ‘miracle’ is also creating a virgin multi-billion dollar industry — and a rare opportunity for early investors.

What’s so special about PIT?
• A diabetic person’s metabolism can now be restored to roughly equal that of a healthy non-diabetic. For the first time, the liver — targeted by the insulin — can now open enzymatic pathways and allow cells to receive and process normal carbohydrates (glucose). This increases a patient’s energy almost immediately!

• People confined to wheelchairs are actually walking again. People with advanced neuropathy facing amputations can actually REVERSE their condition. People with circulatory disease can now work again, and people with the common type of damaged hearts can be “repaired.” (Source: allpennystocks.com)

Here are the recent news about this company:

Diabetic Treatment Centers of America, Inc. Announces Clinic Site in Utah
http://biz.yahoo.com/bw/041021/215097_1.html
Thu 8:30am - Business Wire

Diabetic Treatment Centers of America, Inc. Announces Clinic Site in Utah
http://biz.yahoo.com/prnews/041020/law121_1.html
Wed, Oct 20 - PR Newswire

Patented Technology, Focused Growth, Growing Demand — Arden Oliphant, CEO of Diabetic Treatment Centers of America Inc., Talks with Traders Nation
http://biz.yahoo.com/bw/041020/205896_1.html
Wed, Oct 20 - Business Wire

For the past 3 months, the stock has been performing really well. It went up from $0.7/share to $1.22/share. This might be a good time for you to invest in this company. This is more a long-term investment - since the product has just gotten approved and the company is still trying market the product.

Quote of the Day:
If we command our wealth, we shall be rich and free; if our wealth commands us, we are poor indeed. - A leading efficient market theorist

← Previous Page — Next Page →